GCC Nurse Immunisation & Vaccination Advanced Guide

Immunology Fundamentals

🛡Innate vs Adaptive Immunity

Feature

Innate

Adaptive

Speed

Immediate (minutes–hours)

Days to weeks

Specificity

Nonspecific (PAMPs)

Highly specific (antigen)

Memory

None

Long-lasting memory cells

Key cells

Neutrophils, NK cells, macrophages, DCs

B-lymphocytes, T-lymphocytes

Components

Barriers, complement, cytokines

Antibodies (humoral), CTLs (cellular)

Vaccines exploit the adaptive immune system — they prime memory B and T cells so that re-exposure triggers a rapid, amplified secondary response.

⚡Active vs Passive Immunity

Active Immunity

Host generates own antibodies and memory cells
Natural: infection with live pathogen
Artificial: vaccination — antigen stimulates immune response without disease
Onset: days to weeks
Duration: long-lasting or lifelong (memory cells)
Examples: MMR vaccination, natural measles infection

Passive Immunity

Host receives preformed antibodies from external source
Natural: maternal IgG across placenta; IgA via breast milk
Artificial: immunoglobulin preparations (e.g., HBIg, TIG, RhIg, VZIg)
Onset: immediate
Duration: temporary (weeks to months — antibodies degraded)
No immunological memory produced

Passive immunity provides bridge protection — e.g., HBIg given to neonate of HBsAg+ mother alongside HepB vaccine within 12 hours of birth.

💉Vaccine Types & Examples

Vaccine Type	Mechanism	Key Examples	Considerations
Live-Attenuated	Weakened pathogen — replicates in host, mimics natural infection	MMR, Varicella (chickenpox), Rotavirus, BCG, Yellow Fever, OPV, LAIV (FluMist)	Strongest immunity; 1–2 doses; contraindicated in immunocompromised & pregnancy; cold-chain critical
Inactivated (killed)	Killed whole pathogen — cannot replicate; multiple doses needed	Inactivated Flu (IIV), IPV (polio), Hepatitis A, Rabies, Typhoid Vi (injectable)	Safe in immunocompromised; requires boosters; less potent than live
Subunit / Protein	Specific protein antigens only — no genetic material	Hepatitis B (HBsAg), Pertussis (acellular), Hib (protein conjugate)	Very safe; adjuvants often needed to boost immunogenicity
Toxoid	Inactivated bacterial toxin — induces anti-toxin antibodies	Tetanus toxoid, Diphtheria toxoid (in DTP/Td)	Safe; regular boosters required (every 10 years for tetanus)
mRNA	mRNA encodes antigen (spike protein); expressed by host cells transiently	COVID-19 (Pfizer BNT162b2, Moderna mRNA-1273)	Does not integrate into DNA; ultra-cold storage (Pfizer -70°C); rapid platform
Viral Vector	Adenovirus vector carries antigen gene into cells	COVID-19 (AstraZeneca ChAdOx1, Janssen Ad26)	Associated with rare VITT; single dose (Janssen); good mucosal immunity
Conjugate	Polysaccharide antigen linked to carrier protein — activates T-cell help for infants	Meningococcal ACWY, Pneumococcal (PCV13/PCV15/PCV20), Hib, Typhoid conjugate (TCV)	Overcomes poor infant response to polysaccharides; superior to plain PS vaccines

95%

Herd immunity threshold — Measles (R0 12–18)

80–85%

Herd immunity threshold — Polio (R0 5–7)

Variable

COVID-19 herd immunity (variant-dependent, waning immunity)

🧬Immunological Memory & Vaccine Efficacy vs Effectiveness

B-Cell Memory

Long-lived plasma cells secrete antibodies for years
Memory B cells persist and rapidly differentiate on re-exposure
Affinity maturation improves antibody quality over time
Germinal centre reactions in lymph nodes — key site

T-Cell Memory

CD4+ helper T cells support B cell responses and CD8+ activation
CD8+ cytotoxic T cells kill infected cells directly
Central memory T cells (TCM) in lymph nodes — long-lived
Effector memory T cells (TEM) in tissues — rapid local response

Vaccine Efficacy vs Effectiveness

Efficacy

Measured in randomised controlled trials — ideal conditions; % reduction in disease in vaccinated vs placebo group

Effectiveness

Measured in real-world observational studies — includes suboptimal cold chain, varied populations, waning immunity

Effectiveness is typically lower than efficacy due to real-world variables. Example: mRNA COVID-19 efficacy ~95% in trials; effectiveness ~85–90% in early roll-out.

Correlates of Protection

Antibody titre: measles (≥120 mIU/mL), hepatitis B (>10 mIU/mL)
Not all correlates are well-defined (e.g., TB, RSV)

GCC National Immunisation Schedules

Note: Always verify schedules against the current national health authority publications. Schedules are subject to revision. UAE: MOHAP; Saudi Arabia: MOH; Qatar: QCHP; Kuwait: MOH Kuwait; Bahrain: NHDP; Oman: MOH Oman.

🇦🇪UAE Childhood Immunisation Schedule

Age	Vaccines	Route/Site	Notes
Birth	BCG, Hepatitis B (dose 1)	BCG: ID left arm; HepB: IM thigh	HepB within 24h; BCG before discharge
2 months	DTPw+Hib+IPV (Pentavalent), PCV13, Rotavirus (dose 1), Hep B (dose 2)	IM thigh (x2 sites); oral rotavirus	Minimum age rotavirus: 6 weeks
4 months	DTPw+Hib+IPV (dose 2), PCV13 (dose 2), Rotavirus (dose 2)	As above
6 months	DTPw+Hib+IPV (dose 3), PCV13 (dose 3), HepB (dose 3)	IM thigh	HepB series complete
12 months	MMR (dose 1), Varicella (dose 1), PCV13 (booster)	SC upper arm; IM thigh	MMR + Varicella same visit, different sites
18 months	DTPw booster, MMR (dose 2), Varicella (dose 2)	IM thigh; SC arm
4–6 years	DTP booster, IPV booster	IM deltoid	School entry booster
9–12 years (girls)	HPV (Gardasil 4/9) — 2 doses (0, 6–12 months)	IM deltoid	UAE school-based programme; boys not currently in schedule
Annual (≥6 months)	Influenza (IIV)	IM deltoid/thigh	High-risk groups prioritised; 2 doses first year if <9 years

🇸🇦Saudi Arabia Immunisation Schedule (MOH KSA)

Age	Vaccines	Additional Notes
Birth	BCG, HepB (dose 1)
2 months	DTPa+Hib+IPV+HepB (hexavalent), PCV13, Rotavirus	KSA uses acellular pertussis (DTPa) in primary series
4 months	Hexavalent (dose 2), PCV13 (dose 2), Rotavirus (dose 2)
6 months	Hexavalent (dose 3), PCV13 (dose 3)
12 months	MMR, Varicella, PCV13 booster, Meningococcal ACWY (conjugate)	MenACWY mandatory in KSA — unique to Saudi schedule
18 months	DTPa booster, MMR (dose 2), Varicella (dose 2), Hep A (dose 1)	HepA added given endemic risk
24 months	Hepatitis A (dose 2)
4–6 years	DTPa booster, IPV booster	Pre-school
11–12 years	Tdap booster, HPV (girls), MenACWY booster	MenACWY booster before school/university entry

Mandatory for school entry in KSA: All scheduled vaccines must be documented. MenACWY certificate required for Hajj/Umrah pilgrim entry.

🇶🇦Qatar — QCHP Schedule Highlights

Administered by Qatar Council for Healthcare Practitioners (QCHP)
Birth: BCG (if mother from high TB prevalence country) + HepB
2, 4, 6 months: DTaP-Hib-IPV-HepB + PCV13 + Rotavirus
12 months: MMR + Varicella + PCV13 booster + MenACWY
18 months: MMR booster + Varicella booster + DTaP booster + Hep A
HPV for girls at school (Gardasil 9, 2-dose)
Annual influenza for high-risk groups and children
All expatriate workers: HepB status must be documented on Hamouda Health Platform

🌍Kuwait, Bahrain & Oman — Overview

Kuwait (MOH)

BCG at birth, HepB series, DTP+Hib+IPV, PCV, Rotavirus, MMR, Varicella
MenC conjugate at 12 months; MenACWY for school entry
Annual flu for healthcare workers mandated since 2021

Bahrain (NHDP)

Comprehensive EPI: BCG, HepB, DTPw+Hib+IPV, PCV13, Rotavirus, MMR, Varicella
Hep A at 18 and 24 months
HPV for girls, school-entry boosters

Oman (MOH)

Strong EPI programme — >95% coverage for most antigens
OPV + IPV combination; BCG at birth
MMR, Varicella, PCV, Rotavirus included
Meningococcal ACWY at 12 months and school entry

🕌Hajj & Umrah Mandatory Vaccination Requirements

Mandatory Vaccines

Meningococcal ACWY Conjugate — Mandatory for ALL pilgrims. Certificate required. Valid within 3 years (some countries: 5 years) of Hajj/Umrah. Must be quadrivalent conjugate (NOT plain polysaccharide for <2 years validity in many contexts).

Yellow Fever — Required for pilgrims arriving from yellow fever endemic countries (sub-Saharan Africa, South America). Must be given ≥10 days before travel. Certificate valid for life.

Recommended Vaccines

Seasonal Influenza — Strongly recommended for all pilgrims; mass gatherings amplify transmission significantly.

COVID-19 — Required/recommended per current Saudi MOH policy (check annually). Booster recommended.

Hepatitis A & B, Typhoid, Pneumococcal — Recommended for elderly and at-risk pilgrims.

Historical Context — W135 Outbreak

Hajj 2000–2001 Meningococcal W135 Outbreak: Large outbreak of serogroup W135 meningococcal disease linked to Hajj pilgrims, exported to home countries. This led to mandatory MenACWY conjugate vaccine requirement for all Hajj pilgrims — a landmark in travel vaccination policy.

Nurse Role at Hajj Medical Facilities

Screen vaccination certificates at ports of entry
Administer on-arrival vaccines for unvaccinated pilgrims
Monitor for meningococcal symptoms: sudden fever, neck stiffness, petechiae/purpura
Report suspected cases immediately — notifiable disease
Manage heat-related illness alongside infection surveillance

Visa Medical Requirements (GCC)

UAE: HepB proof for residency visa workers in certain sectors
KSA: Yellow fever certificate for nationals of endemic countries
Qatar: HepB, HIV screening for work permits

Vaccine Administration Technique

💉Routes of Administration

Intramuscular (IM)

90°

Sites: Deltoid (adults/children >1yr) | Anterolateral thigh (infants/<1yr)

Needle gauge: 23–25G

Needle length by weight:
<10 kg → 16 mm
10–30 kg → 25 mm
>30 kg → 25–38 mm
(Obese adults: 38 mm deltoid)

Vaccines: Hep B, DTP, flu (IIV), Hib, PCV, HPV, MenACWY, COVID-19 mRNA

Subcutaneous (SC)

45°

Sites: Upper outer arm (triceps area) | Anterolateral thigh (infants)

Needle: 23–25G, 16 mm

Technique: Pinch skin and fat; inject into fatty layer above muscle

Vaccines: MMR, Varicella, Yellow Fever, some meningococcal polysaccharide

Intradermal (ID)

10–15°

Sites: Left deltoid (BCG standard site in GCC)

Needle: 26G, 10 mm (tuberculin/short bevel)

Technique: Bevel up; raise a visible bleb (6–8 mm); no aspiration; no rubbing after

Vaccines: BCG (Bacille Calmette-Guérin), intradermal rabies

BCG scar: Normal reaction — papule at 2–6 weeks → ulcer → scar by 3 months

Oral

Vaccines: Rotavirus (Rotarix/RotaTeq), OPV (oral polio), Ty21a typhoid (capsule)

Rotavirus: Administer directly into mouth; do not inject; re-dose if spat out; no food/water 30 min before in some guidelines

OPV (no longer used in GCC — switched to IPV): 2 drops oral

Intranasal

Vaccine: LAIV — FluMist (live attenuated influenza)

Technique: 0.1 mL per nostril; do not blow nose for 1 hour

Contraindications: <2 years, >49 years, immunocompromised, pregnancy, severe asthma, aspirin use in children (Reye's risk)

GCC note: Available in UAE and KSA for ages 2–49 years

Pre-Injection Checks

✓

Skin integrity: no active infection/rash at site

5 Rights: Right patient, vaccine, dose, route, time

Check VVM (vaccine vial monitor) — discard if inner square darker than outer

Check expiry date and cold chain temperature log

Consent obtained; allergy history reviewed (eggs, gelatin, neomycin, latex)

📋Key Technique Points

Z-Track Technique (IM)

Displace skin 2–3 cm laterally before inserting needle
Inject at 90°; hold 10 seconds
Release skin as needle withdrawn — seals track
Reduces leakage, tissue irritation, and tattooing
Recommended for all IM vaccine injections

Aspiration — No Longer Recommended

WHO (2015) and ACIP guidance: Aspiration before IM vaccine injection is not recommended. No major blood vessels at recommended IM vaccine sites. Aspiration causes unnecessary pain and delays administration.

Multiple Vaccines Same Visit

Use different anatomical sites — at least 2.5 cm apart
Prefer different limbs when possible
No pharmacokinetic interactions between standard vaccines given simultaneously
Live vaccines: give same day OR separated by ≥4 weeks if not same day
Document site used for each vaccine clearly

❄Cold Chain Management

Storage Requirements by Vaccine Type

Vaccine Category	Storage	Key Risk
Most inactivated vaccines (flu, Hep A/B, IPV)	+2°C to +8°C	Never freeze — aggregation destroys antigen; freezing = discard
Live attenuated (MMR, Varicella, BCG)	+2°C to +8°C; protect from light	Heat sensitive; varicella most sensitive
mRNA COVID-19 (Pfizer)	-60°C to -90°C long-term; 2–8°C for ≤30 days post-thaw	Do not refreeze once thawed
mRNA COVID-19 (Moderna)	-15°C to -25°C; 2–8°C ≤30 days	Less extreme cold than Pfizer

VVM (Vaccine Vial Monitor)

Heat-sensitive colour-change square inside the vaccine vial cap
Inner square must remain lighter than outer circle — safe to use
If inner square = outer circle or darker → DISCARD
VVM does not detect freezing damage — separate freeze indicator needed

Cold Chain Break Actions

Quarantine affected vaccines — do not discard yet

Record temperature excursion details (time, min/max temp)

Contact cold chain officer / pharmacy for stability assessment

Complete incident report — mandatory in GCC facilities

Only discard after formal approval; document batch numbers

Adverse Events & Anaphylaxis Management

✅Common Local Reactions

Redness (erythema), swelling, induration, pain at injection site
Occur in 10–30% of vaccine recipients depending on vaccine
Usually resolve within 48–72 hours
More common with adjuvanted vaccines (Hep B, DTP)

Management

Cold compress (not ice directly) to reduce swelling/pain
Paracetamol for pain if needed (do not pre-dose prophylactically — may blunt immune response)
Reassure parents/patients — expected normal response
Document reaction for AEFI reporting

Observation period: Minimum 15–20 minutes post-vaccination in clinic for all patients. 30 minutes for patients with prior allergic reactions.

⚠️Common Systemic Reactions

Inactivated Vaccines (DTP, flu, PCV)

Fever, irritability, malaise typically within 12–24 hours
Fever usually low-grade (<38.5°C); resolves 24–48h
Persistent inconsolable cry (DTP): uncommon but self-limiting

Live-Attenuated Vaccines (MMR, Varicella)

MMR: fever and mild measles-like rash at 6–14 days post-dose
Varicella: mild varicella-like rash in 3–5% at 5–26 days
Parotid swelling (mumps component): up to 4 weeks post MMR

Febrile Seizures

MMR-associated febrile seizures: Risk approximately 1:3,000 doses, occurring 6–14 days post-vaccination during peak fever. Simple febrile seizures — self-limiting. Risk is far less than seizure risk from natural measles infection (1:200).

⚡Rare Serious Adverse Events

Event	Vaccine	Timing	Incidence	Management
Intussusception	Rotavirus (primarily Rotarix and RotaTeq)	1–3 days after first dose (occasionally dose 2)	~1–5 per 100,000 doses (varies by study)	Urgent paediatric surgical referral; air/hydrostatic enema; surgery if needed
Immune Thrombocytopenic Purpura (ITP)	MMR (measles component)	2–6 weeks post dose	~1 per 25,000–30,000 doses	Usually self-limiting; platelet count monitoring; haematology consult if severe (<20 × 10⁹/L or bleeding)
BCG-itis / BCG osteitis	BCG	Weeks to months	Rare; higher in immunocompromised	Regional lymphadenitis usually self-limiting; disseminated BCG (BCG-osis) requires anti-TB therapy
Vaccine-Strain Viral Infection	OPV (oral polio — not used in GCC)	4–30 days	~1 per 2.5 million doses	GCC uses IPV only — eliminates this risk

🩸VITT — Vaccine-Induced Immune Thrombocytopenia and Thrombosis

What is VITT?

Rare but serious syndrome associated with adenoviral vector COVID-19 vaccines (AstraZeneca ChAdOx1, Janssen Ad26)
Clinically resembles spontaneous HIT (heparin-induced thrombocytopenia)
Occurs 4–30 days post-vaccination
Combination of thrombosis at unusual sites + thrombocytopenia

Mechanism

Vaccine-induced anti-PF4 (platelet factor 4) antibodies
Anti-PF4 IgG activates platelets via FcγRIIa receptors
Results in platelet consumption (thrombocytopenia) + thrombosis
Unusual thrombosis sites: CVST (cerebral venous sinus), splanchnic veins, adrenal veins

Diagnosis

Thrombocytopenia (<150 × 10⁹/L)
Thrombosis (arterial or venous)
Positive anti-PF4 ELISA or functional assay
D-dimer markedly elevated; fibrinogen low

Treatment — CRITICAL

DO NOT USE HEPARIN — heparin-PF4 complexes worsen platelet activation and thrombosis.

IVIG 1 g/kg/day × 2 days — blocks Fc receptor activation
Dexamethasone 40 mg/day × 4 days — suppresses anti-PF4 antibodies
Anticoagulation with non-heparin agents: argatroban, fondaparinux, rivaroxaban
Platelet transfusion: avoid unless life-threatening haemorrhage

ANAPHYLAXIS MANAGEMENT POST-VACCINATION

Recognition (AAAAI Criteria)

Onset within minutes to 1–2 hours of vaccine
Urticaria, angioedema OR flushing/pruritus
Respiratory compromise (wheeze, stridor, desaturation)
Cardiovascular collapse (hypotension, tachycardia, syncope)
Gastrointestinal (vomiting, abdominal pain)
Incidence: approximately 1 per million vaccine doses

Immediate Actions

Call for help; activate emergency response

Lay patient flat; elevate legs (unless respiratory compromise)

Adrenaline (epinephrine) 0.01 mg/kg IM (max 0.5 mg adult) — anterolateral thigh; repeat every 5–15 min if needed

High-flow O₂ via non-rebreather mask; IV access

IV fluid bolus: 0.9% NaCl 10–20 mL/kg if hypotensive

Adrenaline Dosing Guide

Weight	Adrenaline 1:1000 IM
10 kg	0.1 mL (0.1 mg)
20 kg	0.2 mL (0.2 mg)
30 kg	0.3 mL (0.3 mg)
50+ kg (adult)	0.5 mL (0.5 mg)

Secondary Medications

Antihistamine (chlorphenamine IM/IV) — adjunct only, NOT first-line
Hydrocortisone 100–500 mg IV — prevents biphasic reaction
Salbutamol nebuliser — bronchospasm not responding to adrenaline
Glucagon 1–2 mg IV — if patient on beta-blockers

Observation & Follow-Up

Observe 4–12 hours in hospital (biphasic anaphylaxis risk)
Discharge with epinephrine auto-injector (EpiPen) prescription
Allergy referral for skin-prick testing to identify vaccine component culprit
Complete AEFI (Adverse Events Following Immunisation) report

Emergency equipment must be immediately available at all vaccination sites: adrenaline 1:1000, syringes, O₂, IV access, resuscitation equipment.

Special Populations & Catch-Up Immunisation

🚫Immunocompromised Patients

Contraindicated — Live Vaccines in Severe Immunosuppression

Avoid in: Active malignancy on chemotherapy, post-haematopoietic stem cell transplant (<2 years), high-dose corticosteroids (>20 mg/day prednisolone >2 weeks), severe combined immunodeficiency (SCID), anti-TNF therapy, anti-CD20 (rituximab)

Live vaccines to AVOID: MMR, Varicella/Zoster (live), BCG, Yellow Fever, LAIV, Ty21a, OPV

Safe — Inactivated Vaccines

All inactivated vaccines are safe to give
May require higher doses or additional doses (e.g., HepB double dose)
Serological testing post-vaccination to confirm seroconversion
Annual influenza (IIV — not LAIV) strongly recommended
Pneumococcal (PCV + PPSV23), Hib, Meningococcal recommended

Household Contacts

All household contacts of immunocompromised patients should be fully immunised including annual flu and varicella (if non-immune) — cocooning strategy to protect the immunocompromised.

HIV-Positive Patients

CD4 Count	Live Vaccines	Notes
>200 cells/μL	Consider case-by-case — MMR, Varicella generally given	Risk-benefit; MMR recommended if measles risk high
200–350 cells/μL	Caution — specialist guidance	Yellow fever — avoid unless high-risk travel
<200 cells/μL	Avoid all live vaccines	Severely immunocompromised

Inactivated vaccines: all safe at any CD4 count. Annual flu, pneumococcal, HepA, HepB, Tdap recommended for all HIV+ patients regardless of CD4.

Timing Post-Immunosuppressive Therapy

Rituximab: defer live vaccines ≥6 months post last dose; ≥12 months post HSCT
Prednisolone >20 mg/day: defer live vaccines until off ≥4 weeks
Anti-TNF: live vaccines generally safe if ≥3 months off therapy
After HSCT: restart vaccinations per transplant schedule (typically from 6 months post-HSCT)

🤰Pregnancy

Recommended in Pregnancy

Influenza (IIV): Any trimester — reduces severe flu, preterm birth, low birthweight. Safe and highly recommended in GCC given humidity and seasonal flu burden.

Tdap (Tetanus-diphtheria-acellular pertussis): 16–32 weeks gestation — optimal at 20–32 weeks. Transplacental antibody transfer protects neonate against pertussis (cocoon strategy). Repeat with each pregnancy.

COVID-19: Recommended per current GCC health authority guidance. mRNA vaccines safe; booster recommended.

Contraindicated in Pregnancy

Avoid live vaccines: MMR, Varicella, LAIV, Yellow Fever, BCG, Ty21a. Theoretical risk of vaccine-strain infection to fetus. If inadvertently given, not an indication for termination — counsel and monitor.

Yellow Fever Exception

If travel to high-risk YF endemic area is unavoidable: risk-benefit discussion with ID/Obstetrics. YF can be fatal in pregnancy. WHO supports vaccination if risk of exposure is high — document consent.

👶Premature Infants

General Principle

Vaccinate at chronological age (not corrected/gestational age) for most vaccines. Preterm infants have same immunological benefit and are at higher risk of severe vaccine-preventable diseases.

Hepatitis B — Special Rule

If birthweight <2 kg and mother HBsAg negative: delay first HepB dose until 30 days chronological age OR hospital discharge (whichever first)
If mother HBsAg positive: give HepB + HBIg within 12 hours regardless of birthweight — do not delay

While in NICU

DTP, Hib, IPV, PCV, Rotavirus: begin at 2 months chronological age
Rotavirus: can be given in NICU but follow infection control protocol — virus shed in stool
BCG: give at discharge from NICU if not yet administered and no family TB history concern
Influenza: give from 6 months chronological age; household contacts should receive annual flu

🫁Asplenic / Hyposplenic Patients

Vaccines Required

Pneumococcal: PCV15 or PCV20 PLUS PPSV23 (8 weeks apart). Booster PPSV23 every 5 years. Asplenic patients at extremely high risk of overwhelming pneumococcal sepsis (OPSS).

Haemophilus influenzae type b (Hib): 1 dose if not previously vaccinated as adult.

Meningococcal ACWY (conjugate): 2 doses, 8 weeks apart then booster every 5 years.

Meningococcal B (MenB): Recommended if available — 2 doses. Bexsero or Trumenba.

Annual influenza — priority group.

Timing

Elective splenectomy: Vaccinate ideally ≥2 weeks before surgery — better immune response with functional spleen.

Emergency splenectomy: Vaccinate as soon as possible post-operatively (once haemodynamically stable, usually day 5–14). Do not delay indefinitely.

Antibiotic Prophylaxis

Lifelong penicillin V prophylaxis often recommended (amoxicillin in children)
Penicillin allergy: erythromycin or azithromycin
Patient education: medical alert bracelet, early antibiotics for fever, travel precautions

📅Catch-Up Immunisation Principles

Core Principles

Do NOT restart series — continue from where left off
Apply minimum intervals between doses, not maximum
Multiple missed vaccines can be given simultaneously at one visit
Age limits apply: rotavirus max first dose at 14 weeks 6 days; max series completion at 8 months
There is no upper age limit for most catch-up vaccines

Key Minimum Intervals

Vaccine	Min interval doses 1-2	Min interval doses 2-3
HepB	4 weeks	8 weeks (≥16 weeks from dose 1)
DTP	4 weeks	4 weeks
MMR	4 weeks	N/A (2-dose series)
Varicella	4 weeks (≥13 yrs) or 3 months (<13 yrs)	N/A
HPV	4 weeks (3-dose) or 5 months (2-dose)	12 weeks from dose 2
PCV	4 weeks	4 weeks

Serological Testing Before Catch-Up

HepB: test HBsAb — if ≥10 mIU/mL, no vaccination needed
Varicella: IgG if unsure of history — positive = immune, no vaccination needed
MMR: measles/mumps/rubella IgG if uncertain
Yellow fever: neutralisation assay — consider in re-vaccination decisions

Documentation in GCC

UAE: Salama platform (MoHAP) — electronic vaccination record
KSA: Sehhaty app — national vaccination records accessible by nurses
Qatar: CERNER EMR integration with QCHP immunisation registry
Bahrain/Kuwait/Oman: National health records; paper-based backup
Expatriate workers: International Vaccination Certificates (IVC) / Yellow card

Always update the national electronic immunisation registry immediately after vaccination — not at end of shift. Accurate records prevent duplicate doses and gaps.

Vaccine	Type	Countries	Status 2026
Pfizer-BioNTech (BNT162b2)	mRNA	All GCC	Annual updated booster
Moderna (mRNA-1273)	mRNA	UAE, KSA, Qatar	Booster available
AstraZeneca (ChAdOx1)	Viral vector	UAE, KSA (early programme)	Largely phased out post-VITT
Sinopharm (BBIBP-CorV)	Inactivated	UAE (primary)	Booster with mRNA recommended
Sputnik V	Viral vector	Limited GCC use	Limited distribution